These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36052936)

  • 1. Case of buprenorphine-associated central sleep apnea resolving with dose reduction.
    Tchikrizov V; Richert AC; Bhardwaj SB
    J Opioid Manag; 2022; 18(4):391-394. PubMed ID: 36052936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sleep-disordered breathing in patients with opioid use disorders in long-term maintenance on buprenorphine-naloxone: A case series.
    DeVido J; Connery H; Hill KP
    J Opioid Manag; 2015; 11(4):363-6. PubMed ID: 26312963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
    Srivastava A; Kahan M; Nader M
    Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sleep disordered breathing in patients receiving therapy with buprenorphine/naloxone.
    Farney RJ; McDonald AM; Boyle KM; Snow GL; Nuttall RT; Coudreaut MF; Wander TJ; Walker JM
    Eur Respir J; 2013 Aug; 42(2):394-403. PubMed ID: 23100497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flexible Buprenorphine/Naloxone Treatment Models: Safe and Effective in Reducing Opioid Use Among Persons With Prescription Opioid Use Disorder.
    Saunders EC
    Am J Psychiatry; 2022 Oct; 179(10):699-701. PubMed ID: 36181331
    [No Abstract]   [Full Text] [Related]  

  • 6. High-dose tramadol conversion to buprenorphine-naloxone.
    Kirk JK; Boyd CT; Cassidy-Vu L; McRae LP; Strickland HE; Fagan EB
    J Opioid Manag; 2023; 19(2):187-190. PubMed ID: 37270427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Naloxone Component of Buprenorphine/Naloxone: Discouraging Misuse, but at What Cost?
    Gregg J; Hartley J; Lawrence D; Risser A; Blazes C
    J Addict Med; 2023 Jan-Feb 01; 17(1):7-9. PubMed ID: 35913990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of buprenorphine vs methadone on sleep breathing disorders.
    Adimi Naghan P; Setareh J; Malekmohammad M
    Adv Respir Med; 2021; 89(4):439-443. PubMed ID: 33871044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone.
    Kazi I; Chenoweth MJ; Jutras-Aswad D; Ahamad K; Socias ME; Le Foll B; Tyndale RF
    Clin Pharmacol Ther; 2024 Mar; 115(3):506-514. PubMed ID: 38009933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 11. Sublingual buprenorphine-naloxone precipitated withdrawal-A case report with review of literature and clinical considerations.
    Bhatia G; Sarkar S
    Asian J Psychiatr; 2020 Oct; 53():102121. PubMed ID: 32460142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine alone or with naloxone: Which is safer?
    Kelty E; Cumming C; Troeung L; Hulse G
    J Psychopharmacol; 2018 Mar; 32(3):344-352. PubMed ID: 29433352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder.
    Evans EA; Zhu Y; Yoo C; Huang D; Hser YI
    Addiction; 2019 Aug; 114(8):1396-1404. PubMed ID: 30916463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
    Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
    J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transition from Oxycodone to Buprenorphine/Naloxone in a Hospitalized Patient with Sickle Cell Disease: A Case Report.
    Leyde S; Suen L; Pratt L; DeFries T
    J Gen Intern Med; 2022 Apr; 37(5):1281-1285. PubMed ID: 34993878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report.
    Coish R; Hardial J
    J Addict Med; 2023 Jan-Feb 01; 17(1):114-116. PubMed ID: 35916416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the evidence to explain pharmacological basis of injection (ab)use of buprenorphine-naloxone tablets.
    Modak T; Sarkar S; Balhara YPS
    J Opioid Manag; 2021; 17(7):141-152. PubMed ID: 34520035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of buprenorphine/naloxone maintenance treatment on sexual dysfunction, sleep and weight in opioid use disorder patients.
    Baykara S; Alban K
    Psychiatry Res; 2019 Feb; 272():450-453. PubMed ID: 30611963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.